• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SD filed by Waters Corporation

    5/29/26 4:15:28 PM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $WAT alert in real time by email
    SD 1 d346779dsd.htm SD SD
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM SD

     

     

    Specialized Disclosure Report

     

     

    Waters Corporation

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   001-14010   13-3668640

    (State or other jurisdiction

      (Commission   (I.R.S. Employer
    of incorporation)   file number)   Identification No.)
    34 Maple Street, Milford, Massachusetts     01757
    (Address of principal executive offices)     (Zip code)

    Keeley A. Aleman

    Corporate Secretary

    Waters Corporation

    508-478-2000

    (Name and telephone number, including area code, of the person to contact in connection with this report.)

     

     

    Check the appropriate box to indicate the rule pursuant to which this form is being filed:

     

    ☒

    Rule 13p-1 under the Securities Exchange Act (17 CFR 240.13p-1) for the reporting period from January 1 to December 31, 2025.

     

    ☐

    Rule 13q-1 under the Securities Exchange Act (17 CFR 240.13q-1) for the fiscal year ended.

     

     
     


    Section 1 - Conflict Minerals Disclosure

    Item 1.01 Conflict Minerals Disclosure

    This filing is being made by Waters Corporation (“Waters,” the “Company,” “we,” “us,” or “our”) for the calendar year January 1 to December 31, 2025, in accordance with Rule 13p-1 (“Rule 13p-1”) under the Securities Exchange Act of 1934 (the “1934 Act”) and Form SD (collectively, the “Conflict Minerals Rule”). Consistent with the Conflict Minerals Rule, as used herein, “Conflict Minerals” or “3TG” are tin (cassiterite), tungsten (wolframite), tantalum (columbite-tantalite or coltan) and gold. In accordance with the Updated Statement on the Effect of the Court of Appeals Decision on the Conflict Minerals Rule issued by the Division of Corporation Finance of the Securities and Exchange Commission on April 7, 2017, we have not included a Conflict Minerals Report exhibit as part of this filing.

    Company Overview

    Waters is a specialty measurement company that operates with a fundamental purpose to advance the science that enables our customers to enhance human health and well-being. The Company has pioneered analytical workflow solutions involving liquid chromatography, mass spectrometry, thermal analysis and light scattering innovations serving the life, materials, and food sciences.

     

      •  

    Waters sells and services high performance liquid chromatography, ultraperformance liquid chromatography and mass spectrometry technology systems and support products, including chromatography columns, other consumable products, and comprehensive post-warranty service plans. These systems are complementary products that are frequently employed together and sold as integrated instrument systems using common software platforms.

     

      •  

    Waters is also a developer and supplier of advanced software-based products that interface with the Company’s instruments, as well as other manufacturers’ instruments.

     

      •  

    Through its TA Instruments product line, the Company designs, manufactures, sells, and services thermal analysis, rheology and calorimetry instruments.

     

      •  

    Through Wyatt Technology (a business acquired by Waters in May 2023), Waters researches, develops and commercializes light scattering instruments used in pharmaceutical and biotechnology companies and academic institutions.

    Product Scoping; Reasonable Country of Origin Inquiry (“RCOI”)

    The Company determined that 3TG are used in certain components contained in the Company’s instrument systems, which are products that the Company manufactures. These 3TG are necessary to the functionality or production of the Company’s instrument systems.

    As required by the Conflict Minerals Rule, the Company conducted a RCOI to determine whether any of the 3TG in the Company’s products originate in the Democratic Republic of the Congo (the “DRC”) or its adjoining countries or are from recycled or scrap sources. The Company’s due diligence program is based upon industry guidance published by the Organisation for Economic Co-operation and Development, the Due Diligence Guidance for Responsible Supply Chains of Minerals from Conflict-Affected and High-Risk Areas (the “OECD Guidance”).

    As part of our RCOI, we asked 6,498 potentially in-scope suppliers to complete the Conflict Minerals Reporting Template (“CMRT”), developed by the Responsible Minerals Initiative (the “RMI”). The CMRT includes questions about suppliers’ uses and sourcing of 3TG, as well as questions about their own due diligence measures. All potentially in-scope suppliers received a letter from the Company’s Senior Vice President of Global Operations requesting their compliance with the annual RCOI process.

    Due Diligence Program

    The Company has designed its due diligence program to align with ongoing compliance with the Conflict Minerals Rule. As recommended by the OECD Guidance, the Company published a Conflict Minerals Statement, which is made available to employees, suppliers and the public on our website at https://www.waters.com/nextgen/us/en/about-waters/corporate-governance/conflict-minerals-statement.html. Among other things, the Company’s due diligence program includes the review of its worldwide supply chain for materials that contain 3TG and the evaluation of the risk that these materials are from sources that directly or indirectly finance or benefit armed groups in the DRC or an adjoining country.

    The Company’s program has several elements including, but not limited to, the following:

     

      •  

    Establishing a cross-functional team with representation from Product Stewardship, Trade Compliance, Procurement, Sustainability, Legal, Finance, and Investor Relations to monitor supply chain due diligence and reporting. Waters has permanent staff dedicated to the management of this program.

     

      •  

    Having a Supplier Environmental and Social Responsibility (ESR) Code of Conduct. Pursuant to the ESR Code of Conduct, the Company expects its suppliers to exercise due diligence on their own supply chains and to make their due diligence findings available to the Company. The ESR Code of Conduct indicates that the Company reserves the right to take remedial action up to and including termination in the event of supplier non-compliance.


      •  

    Including language in the Company’s purchase order terms and conditions related to Conflict Minerals reporting and compliance.

     

      •  

    Holding periodic virtual training with certain critical suppliers about our Conflict Minerals compliance program, our reporting obligations, and the importance of supplier participation.

     

      •  

    Engaging with a third-party vendor to administer the supplier survey, to tabulate survey results, and to help measure year-over-year performance.

     

      •  

    Utilizing our Conflict_Minerals@waters.com email as a mechanism for our suppliers and other third parties to report compliance questions or issues to the Company.

     

      •  

    Notifying the Company’s Procurement organization about suppliers who do not respond to the RCOI.

     

      •  

    In certain circumstances where a supplier acknowledges the use of smelters not certified by the RMI, removing the supplier from the Company’s approved vendor list.

    Findings and Results

    For calendar year 2025, the Company identified 6,498 potentially in-scope suppliers, an increase from 6,380 in the prior year. This increase reflects the addition of new suppliers in the ordinary course of business as well as additional supplier responses. The Company’s methodology is designed to enhance visibility into its products and their components, including components that are considered to present a lower risk of containing Conflict Minerals.

    During calendar year 2025, the Company received responses from approximately 76% of the potentially in-scope suppliers contacted, representing a 3.2% increase in supplier response rate compared to the prior year. The responses received were applicable to approximately 85% of the 99,915 parts supplied by responding suppliers.

    Based on the information collected through its RCOI:

     

      •  

    Some suppliers indicated that the products, components, or materials they supplied to the Company did not contain 3TG, or that any 3TG contained in those products was sourced exclusively from smelters and refiners that conformed with the Responsible Minerals Initiative’s Responsible Minerals Assurance Process (“RMAP”).

     

      •  

    Some suppliers reported that they were unable to determine the smelters or refiners that processed the 3TG used in the products, components, or materials sold to the Company, or were unable to determine the country of origin of such 3TG.

     

      •  

    No suppliers reported, in response to the Company’s RCOI survey, that they sourced 3TG from mines located in the DRC or adjoining countries that are controlled by armed groups.

    As a result of the information received from its suppliers for calendar year 2025, the Company was unable to determine with certainty the country of origin of the 3TG used in its products. However, based on the information obtained and its RCOI efforts, the Company does not have reason to believe that the 3TG contained in its products originated from mines located in the DRC or adjoining countries that are controlled by armed groups.

    Future Due Diligence Considerations

    The Company is committed to continuing to evolve our RCOI and due diligence program. The Company intends to work to improve survey response rates from its suppliers over time. The Company also intends to continue to update our RCOI and due diligence program processes and procedures as appropriate.

    The Company’s Form SD is publicly available on our website at https://ir.waters.com/financials/sec-filings. Links to websites included in this Form SD are provided solely for information and convenience. The content on any websites named, hyperlinked, or otherwise referenced herein, including the content of any reports that are noted as being posted on our website, is not, and shall not be deemed to be, incorporated by reference into this Form SD or into any of our other filings with the Securities and Exchange Commission.

    Section 2 - Resource Extraction Issuer Disclosure

    Item 2.01 Resource Extraction Issuer Disclosure and Report

    Not applicable.

    Section 3 - Exhibits Item 3.01 Exhibits

    Not applicable.


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the duly authorized undersigned.

     

        WATERS CORPORATION
    Dated: May 29, 2026     By:  

    /s/ Christos Ross

        Name:   Christos Ross
        Title:   Senior Vice President, Global Operations
    Get the next $WAT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $WAT

    DatePrice TargetRatingAnalyst
    6/2/2026$425.00Outperform
    Wolfe Research
    4/6/2026$350.00In-line → Outperform
    Evercore ISI
    2/10/2026$360.00In-line
    Evercore ISI
    2/10/2026$425.00Buy
    Citigroup
    2/10/2026$400.00Overweight
    Barclays
    1/6/2026$440.00Buy
    Guggenheim
    1/5/2026Outperform
    William Blair
    12/10/2025$480.00Peer Perform → Outperform
    Wolfe Research
    More analyst ratings

    $WAT
    SEC Filings

    View All

    SEC Form SD filed by Waters Corporation

    SD - WATERS CORP /DE/ (0001000697) (Filer)

    5/29/26 4:15:28 PM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 8-K filed by Waters Corporation

    8-K - WATERS CORP /DE/ (0001000697) (Filer)

    5/22/26 4:15:20 PM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 10-Q filed by Waters Corporation

    10-Q - WATERS CORP /DE/ (0001000697) (Filer)

    5/12/26 4:16:20 PM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $WAT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SVP & Chief Financial Officer Chaubal Amol covered exercise/tax liability with 239 shares, decreasing direct ownership by 3% to 7,623 units (SEC Form 4) to satisfy withholding obligation

    4 - WATERS CORP /DE/ (0001000697) (Issuer)

    5/14/26 4:55:54 PM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 4 filed by Bennett Jianqing

    4 - WATERS CORP /DE/ (0001000697) (Issuer)

    4/7/26 4:36:35 PM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 4 filed by Jiang Wei

    4 - WATERS CORP /DE/ (0001000697) (Issuer)

    4/2/26 5:03:05 PM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $WAT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wolfe Research resumed coverage on Waters with a new price target

    Wolfe Research resumed coverage of Waters with a rating of Outperform and set a new price target of $425.00

    6/2/26 8:40:09 AM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Waters upgraded by Evercore ISI with a new price target

    Evercore ISI upgraded Waters from In-line to Outperform and set a new price target of $350.00

    4/6/26 8:29:42 AM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Evercore ISI resumed coverage on Waters with a new price target

    Evercore ISI resumed coverage of Waters with a rating of In-line and set a new price target of $360.00

    2/10/26 8:10:12 AM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $WAT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Waters Announces FDA 510(k) Clearance of BD BACTEC FXI Culture System, Enabling Broader Access to Bloodstream Infection Diagnostics

    FDA 510(k)-cleared BD BACTEC™ FXI Culture System now available to U.S. market, enabling broader access to confident bloodstream infection diagnostics.Achieves a 3-hour faster time to detection (~15% reduction) versus the prior-generation system, per clinical study data, enabling earlier targeted sepsis prevention.Fully automated solution delivers an industry-leading 50% increase in vial loading and up to 960-vial per module capacity, maximizing walk-away time.MILFORD, Mass., June 3, 2026 /CNW/ -- Waters Corporation (NYSE:WAT) today announced that the BD BACTEC FXI Culture System has received U.S. Food and Drug Administration (FDA) 510(k) clearance. This clearance enables commercialization in

    6/3/26 8:00:00 AM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Waters Introduces Unrivaled Sensitivity and Speed to Benchtop HRMS with Xevo MRT P10 MS, Accelerating Multiomics Research

    Delivers up to 20x improvement in MS/MS sensitivity and 2x faster acquisition speeds, enabling deeper biological insight for next-generation multiomics, therapeutic, and high-throughput workflows.Identifies up to 40% more lipids by LC‑MS/MS than the leading alternative benchtop high‑resolution mass spectrometer, advancing lipidomics research and disease understanding.Sets a new benchmark for throughput in high-resolution spatial analysis with the DESI XS source, supporting higher-confidence studies of disease and treatment response.MILFORD, Mass., June 1, 2026 /CNW/ -- 74th ASMS Conference on Mass Spectrometry and Allied Topics—Waters Corporation (NYSE:WAT) today introduced the Waters Xevo™

    6/1/26 8:00:00 AM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Waters Unveils Cyclic IMS P20 MS: The New Benchmark in Structural and Spatial Omics

    >10x step-change in MS/MS sensitivity paired with multipass Cyclic™ Ion Mobility Spectrometry (IMS) reveals subtle biological differences for earlier, previously unattainable detection of disease signals.50% extended upper mass range and comprehensive suite of structural tools advance the development of next-generation biotherapeutics.Integrated MALDI XS and DESI XS imaging with high-resolution ion mobility enables direct visualization of molecules in tissue, improving understanding of how disease develops at the cellular level.MILFORD, Mass., June 1, 2026 /PRNewswire/ -- 74th ASMS Conference on Mass Spectrometry and Allied Topics— Waters Corporation (NYSE:WAT) today announced the launch of

    6/1/26 8:00:00 AM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $WAT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Fearon Richard H bought $306,340 worth of shares (1,000 units at $306.34), increasing direct ownership by 43% to 3,302 units (SEC Form 4)

    4 - WATERS CORP /DE/ (0001000697) (Issuer)

    3/10/26 4:21:34 PM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Fearon Richard H bought $332,900 worth of shares (1,000 units at $332.90), increasing direct ownership by 153% to 1,653 units (SEC Form 4)

    4 - WATERS CORP /DE/ (0001000697) (Issuer)

    5/29/24 11:23:35 AM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $WAT
    Financials

    Live finance-specific insights

    View All

    Waters Corporation (NYSE: WAT) Reports First Quarter 2026 Financial Results

    First Quarter 2026 HighlightsTotal reported revenue of $1.267 billion exceeded the high end of the guidance range by $56 million, driven by strong outperformance in both organic revenue and the acquired businesses.Organic revenue grew 13% as reported and 11% in constant currency, exceeding the high end of the constant currency growth guidance range by 200 basis points – led by high-single-digit instrument growth and mid-teens chemistry growth within the Analytical Sciences Division.The Biosciences and Diagnostic Solutions businesses generated $520 million of reported revenue since the closing of the acquisition – $40 million above guidance – driven by traction from commercial execution and o

    5/5/26 6:00:00 AM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Waters Corporation Schedules First Quarter 2026 Earnings Conference Call

    MILFORD, Mass., April 20, 2026 /PRNewswire/ -- Waters Corporation (NYSE:WAT) will hold its Q1 2026 financial results conference call on Tuesday, May 5, 2026 at 8:30 a.m. Eastern Time. A live webcast of the presentation will be available on Waters Investor Relations website at https://ir.waters.com. A replay of the webcast will also be available until at least June 2, 2026, at midnight Eastern Time. About Waters CorporationWaters Corporation (NYSE:WAT) is a global leader in life sciences and diagnostics, dedicated to accelerating the benefits of pioneering science through analytical technologies, informatics, and service. With a focus on regulated, high-volume testing environments, our innova

    4/20/26 4:15:00 PM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Waters Corporation (NYSE: WAT) Reports Fourth Quarter and Full-Year 2025 Financial Results

    Highlights Fourth Quarter 2025 Sales of $932 million landed at the high-end of reported sales growth guidance range; grew 7% as reported and 6% in constant currencyGrowth led by high single-digit constant currency growth in Pharma and Industrial end-markets, with broad-based growth across all regionsChemistry grew 12% in constant currency as new bioseparations products continued to experience significant customer demandInstruments grew 3% in constant currency, with high single-digit LC-MS growth partially offset by TA and transition to subscription model for EmpowerGAAP EPS of $3.77; non-GAAP EPS of $4.53 grew double digitsFull-Year 2025 Sales of $3,165 million grew 7% as reported and 7% in

    2/9/26 6:30:00 AM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $WAT
    Leadership Updates

    Live Leadership Updates

    View All

    Waters Completes Combination with BD's Biosciences & Diagnostic Solutions Businesses

    Announces appointment of Claire M. Fraser, Ph.D., to its Board of DirectorsForms a global life sciences and diagnostics leader focused on high-volume testing in regulated applicationsAnnounces formation of four divisions: Waters Analytical Sciences, Waters Biosciences, Waters Advanced Diagnostics, and Waters Materials SciencesMILFORD, Mass., Feb. 9, 2026 /PRNewswire/ -- Waters Corporation (NYSE:WAT) ("Waters") today announced it has completed the previously announced combination with the Biosciences & Diagnostic Solutions businesses of Becton, Dickinson and Company (NYSE:BDX) ("BD"). The transaction forms a global life sciences and diagnostics leader, equipped with best-in-class technologies

    2/9/26 8:40:00 AM ET
    $BDX
    $WAT
    Medical/Dental Instruments
    Health Care
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Waters Acquires Halo Labs, Expanding Biological Analysis Portfolio

    MILFORD, Mass., May 21, 2025 /PRNewswire/ -- Waters Corporation (NYSE:WAT) today announced that it has acquired Halo Labs™, an innovator of specialized imaging technologies to detect, identify, and count interfering materials (particles) in therapeutic products, such as cell, protein, and gene therapies. The Aura™ platform from Halo Labs features a highly differentiated technology that performs full spectrum particle analysis and is complementary to the Waters light scattering detection solutions from its Wyatt Technology™ Portfolio. For example, its subvisible particle technology unlocks additional insights when characterizing external particles used to amplify CAR T-cells for cell therapy,

    5/21/25 8:00:00 AM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Waters Corporation Appoints Heather Knight to Board of Directors

    MILFORD, Mass., Aug. 14, 2024 /PRNewswire/ -- Waters Corporation (NYSE:WAT) today announced the appointment of Heather Knight to its Board of Directors effective August 14, 2024. Ms. Knight currently serves as Executive Vice President and Group President, Medical Products and Therapies at Baxter International. Heather is an accomplished leader who brings decades of experience across the pharma and medical device industries."Heather is an accomplished leader who brings decades of experience across the pharmaceutical and medical device industries, with a proven track record for

    8/14/24 4:15:00 PM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $WAT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Waters Corporation

    SC 13G/A - WATERS CORP /DE/ (0001000697) (Subject)

    11/12/24 11:54:03 AM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G/A filed by Waters Corporation (Amendment)

    SC 13G/A - WATERS CORP /DE/ (0001000697) (Subject)

    2/14/24 9:37:22 AM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G/A filed by Waters Corporation (Amendment)

    SC 13G/A - WATERS CORP /DE/ (0001000697) (Subject)

    2/13/24 5:17:31 PM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials